상피성 난소암에서 항암약물요법(CT 또는 PT)과 ATP-CRA검사의 연관성 (Correlation for ATP-CRA and Chemotherapy(CT or PT regimen) in Epithelial Ovarian Cancer)

서지정보

· 발행기관 : 고신대학교(의대) 고신대학교 의과대학 학술지
· 수록지 정보 : 고신대학교 의과대학 학술지 / 23권 / 4호 / 148 ~ 154페이지
· 저자명 : 이천준, 김원규

초록

Background: The behavior of cancer can be very varied with different individual responses to chemotherapy.
Individualization is crucial to the optimization of chemotherapy. The individualized chemotherapy sensitivity test has been introduced to help in the selection of the appropriate drug for each individual patient but disappointing results achieved with old chemosensitivity tests. The development of the adenosine triphosphate based chemotherapy response assay(ATP-CRA) was designed to overcome the limitations of many in vitro chemotherapy sensitivity tests. The aims of this study were to predict accurately the ATP-CRA and a patient's clinical response to chemotherapy(CT(carboplatin, paclitaxel), PT(cisplatin, paclitaxel)) in epithelial ovarian cancer and to assess the clinical efficacy of the ATP-CRA.
Materials and Methods: The study was performed on 34 patients who is diagnosed initially the epithelial ovarian cancer for chemotherapy after operation at Gospel hospital of Kosin university between March 2005 and December 2007.
The ATP-CRA was evaluated the chemosensitivities of nine anticancer drugs for epithelial ovarian cancer. To investigate the correlation between ATP-CRA and clinical outcomes in patients with epithelial ovarian cancer, it was compared the clinical responses with the results of CSA retrospectively. Statistical analysis was performed using the Fisher's exact test.
Results: The mean chemosensitivity index(CI) tested by the ATP-CRA, were 186.4(carboplatin), 167.9(cisplatin) and 194.1(paclitaxel) respectively. The Cisplatin showed the most effective effect. The sensitivity and specificity of ATP-CRA were 96.4% and 50.0%. The positive and negative response prediction values were 90.0% and 75.0%. The accuracy rate was 88.2%. There was a significant relationship between the results of ATP-CRA and clinical responses(p =0.04).
Conclusions: This study shows that ATP-CRA could be used clinically to predict chemoresponse in epithelial ovarian cancer. However, prospective randomized clinical trials in a larger patient cohort are warranted to confirm the clinical correlation of ATP-CRA

영어초록

Background: The behavior of cancer can be very varied with different individual responses to chemotherapy.
Individualization is crucial to the optimization of chemotherapy. The individualized chemotherapy sensitivity test has been introduced to help in the selection of the appropriate drug for each individual patient but disappointing results achieved with old chemosensitivity tests. The development of the adenosine triphosphate based chemotherapy response assay(ATP-CRA) was designed to overcome the limitations of many in vitro chemotherapy sensitivity tests. The aims of this study were to predict accurately the ATP-CRA and a patient's clinical response to chemotherapy(CT(carboplatin, paclitaxel), PT(cisplatin, paclitaxel)) in epithelial ovarian cancer and to assess the clinical efficacy of the ATP-CRA.
Materials and Methods: The study was performed on 34 patients who is diagnosed initially the epithelial ovarian cancer for chemotherapy after operation at Gospel hospital of Kosin university between March 2005 and December 2007.
The ATP-CRA was evaluated the chemosensitivities of nine anticancer drugs for epithelial ovarian cancer. To investigate the correlation between ATP-CRA and clinical outcomes in patients with epithelial ovarian cancer, it was compared the clinical responses with the results of CSA retrospectively. Statistical analysis was performed using the Fisher's exact test.
Results: The mean chemosensitivity index(CI) tested by the ATP-CRA, were 186.4(carboplatin), 167.9(cisplatin) and 194.1(paclitaxel) respectively. The Cisplatin showed the most effective effect. The sensitivity and specificity of ATP-CRA were 96.4% and 50.0%. The positive and negative response prediction values were 90.0% and 75.0%. The accuracy rate was 88.2%. There was a significant relationship between the results of ATP-CRA and clinical responses(p =0.04).
Conclusions: This study shows that ATP-CRA could be used clinically to predict chemoresponse in epithelial ovarian cancer. However, prospective randomized clinical trials in a larger patient cohort are warranted to confirm the clinical correlation of ATP-CRA

참고자료

· 없음